Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127323 | 0.87 | PTGER1 (0.37) | NPY2RCCNE1CDK2GSK3BUSP30 | |
| SCHEMBL3127036 | 0.84 | NPY2R (0.43) | NPY2RCCNE1CDK2GSK3B | |
| SCHEMBL3124512 | 0.77 | CDK2 (0.48) | CCNE1CDK2GSK3B | |
| SCHEMBL3127317 | 0.71 | NPY2R (0.43) | NPY2RCCNE1CDK2GSK3BPTGER1 | |
| SCHEMBL3252851 | 0.67 | CYP3A4 (0.41) | NPY2RCCNE1CDK2GSK3BPTGER1 | |
| SCHEMBL11966180 | 0.66 | KCNJ6 (0.43) | CCNE1CDK2GSK3BUSP30GPR119 | |
| SCHEMBL3131592 | 0.66 | CDK2 (0.46) | CCNE1CDK2GSK3B | |
| SCHEMBL3131586 | 0.66 | CDK2 (0.46) | CCNE1CDK2GSK3B | |
| SCHEMBL3257048 | 0.63 | CCNE1 (0.39) | CCNE1CDK2GSK3BHTR2CSLC6A4 | |
| SCHEMBL3257050 | 0.63 | CCNE1 (0.39) | CCNE1CDK2GSK3BHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689721-B1 | AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| EP-1689721-A1 | AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051919-A1 | AMINOPYRAZOLE DERIVATIVES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | NPY2R 876/4885CCNE1 420/4885CDK2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.